Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor
about
Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapyA Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.SET and MYND domain containing protein 3 in cancer.Inhibitors of Protein Methyltransferases and Demethylases.Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.Design and synthesis of selective, small molecule inhibitors of coactivator-associated arginine methyltransferase 1 (CARM1).Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase.Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck.TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma.Identification of a peptide inhibitor for the histone methyltransferase WHSC1.Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery.
P2860
Q26769943-09D53900-5D10-49C8-841D-9347EA618488Q36703511-25077341-CFD2-4158-860C-7840B216224CQ37596853-A7C8FEAE-53C2-4B0B-A07D-96628FBC350BQ38740496-E0012A8B-0EFA-48BA-9BEA-164416175154Q38975402-16FA1280-941F-44A7-BD75-8E575EC11FAFQ39055609-14AA463D-259F-4735-A66A-D36D8F2CE36EQ40269933-C9B2F85B-875C-433F-A8E9-9B85DB03B72AQ42383290-96FB6C12-E25E-4159-85A6-048406A04E09Q44682016-D3A160BA-B6AC-424F-ACBF-9F310F3C10ACQ49180652-5144D7E7-C34C-40FD-A59F-3FBA51EE4B39Q52714602-ED452309-B072-4625-B6F3-6F4D61C87F68Q55104676-17CFD602-3B76-4827-BB01-E1EFC1A8F9BDQ55129685-C035F0AB-B9D2-4E3E-AD4B-29B4FB60B0BEQ55314041-A3FF1363-245F-4C31-A64F-062D3EE5C69E
P2860
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Novel Oxindole Sulfonamides an ...... Small Molecule SMYD3 Inhibitor
@ast
Novel Oxindole Sulfonamides an ...... Small Molecule SMYD3 Inhibitor
@en
type
label
Novel Oxindole Sulfonamides an ...... Small Molecule SMYD3 Inhibitor
@ast
Novel Oxindole Sulfonamides an ...... Small Molecule SMYD3 Inhibitor
@en
prefLabel
Novel Oxindole Sulfonamides an ...... Small Molecule SMYD3 Inhibitor
@ast
Novel Oxindole Sulfonamides an ...... Small Molecule SMYD3 Inhibitor
@en
P2093
P2860
P1476
Novel Oxindole Sulfonamides an ...... Small Molecule SMYD3 Inhibitor
@en
P2093
Alejandra Raimondi
Christine Klaus
James E Mills
Jennifer Totman
Jesse J Smith
Kevin W Kuntz
Lorna H Mitchell
Margaret Porter Scott
Megan Foley
P2860
P304
P356
10.1021/ACSMEDCHEMLETT.5B00272
P50
P577
2015-08-27T00:00:00Z